Skip to search formSkip to main contentSkip to account menu

lipegfilgrastim

A long acting glyco-pegylated recombinant form of human granulocyte colony-stimulating factor (G-CSF), with hematopoietic activity. Similar to G-CSF… 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

XM22pegfilgrastim

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
Meta-analysis and indirect treatment comparison of lipegfilgrastim with pegfilgrastim and filgrastim for the reduction of chemotherapy-induced neutropenia-related events
Background Granulocyte colony-stimulating factors are effective at reducing the risk and duration of neutropenia. The current… 
Review
2017
Review
2017
Refining the role of pegfilgrastim (a long-acting G-CSF) for prevention of chemotherapy-induced febrile neutropenia: consensus guidance recommendations
PurposeChemotherapy-induced febrile neutropenia (FN) causes treatment delays and interruptions and can have fatal consequences… 
2015
2015
Chemotherapy-associated treatment burden in breast cancer patients receiving lipegfilgrastim or pegfilgrastim: secondary efficacy data from a phase III study
PurposeLipegfilgrastim is a once-per-cycle glycoPEGylated granulocyte colony-stimulating factor (G-CSF). Noninferiority of… 
2015
2015
Phase III, randomized, double-blind, placebo-controlled, multicenter study of lipegfilgrastim in patients with non-small cell lung cancer receiving myelosuppressive therapy
PurposeThe aim of this study was to demonstrate lipegfilgrastim superiority versus placebo in adults with non-small cell lung… 
Review
2015
Review
2015
Efficacy, effectiveness and safety of long-acting granulocyte colony-stimulating factors for prophylaxis of chemotherapy-induced neutropenia in patients with cancer: a systematic review
PurposePegfilgrastim was introduced over a decade ago. Other long-acting granulocyte colony-stimulating factors (G-CSFs) have… 
Review
2014
Review
2014
The impact of primary prophylaxis with granulocyte colony-stimulating factors on febrile neutropenia during chemotherapy: a systematic review and meta-analysis of randomized controlled trials
PurposeThe study aims to assess the relative efficacy of granulocyte colony-stimulating factor (G-CSF) products administered as… 
2014
2014
Lipegfilgrastim: pharmacodynamics and pharmacokinetics for body-weight-adjusted and 6 mg fixed doses in two randomized studies in healthy volunteers
Abstract Objective: Two phase I, single-blind (subject blinded to treatment), randomized studies were conducted to assess the… 
Review
2013
Review
2013
Efficacy and safety of lipegfilgrastim versus pegfilgrastim: a randomized, multicenter, active-control phase 3 trial in patients with breast cancer receiving doxorubicin/docetaxel chemotherapy
AbstractBackgroundLipegfilgrastim is a novel glyco-pegylated granulocyte-colony stimulating factor in development for neutropenia… 
2013
2013
Rational Development Of Lipegfilgrastim, a Novel Long-Acting Granulocyte Colony-Stimulating Factor, Using Glycopegylation Technology
Introduction Recombinant human granulocyte colony-stimulating factors (G-CSFs) are indicated for the prevention of chemotherapy… 
2013
2013
Lipegfilgrastim: A long-acting, once-per-cycle, glycopegylated recombinant human filgrastim.
e13548 Background: Lipegfilgrastim is a once-per-cycle fixed-dose glycoPEGylated granulocyte-colony stimulating factor (G-CSF… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)